Propanc Health Group Corporation — Form 10-Q Summary
Reporting period: The filing covers the three and six months ended December 31, 2014, with balance-sheet comparisons to June 30, 2014. Although the request identifies 2014 Q2, the filing’s stated period is the quarter ended December 31, 2014. Financial statements are unaudited and reported in U.S. dollars.
Business context
The company is an Australian-based cancer-treatment research and development business. It reported no products available for sale and no products in clinical trials; its lead product was in preclinical development. It said substantial additional financing is required to advance development.
Financial performance and liquidity
| Metric | Three months ended Dec. 31, 2014 | Six months ended Dec. 31, 2014 | Comparable 2013 period |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Operating expenses | $249,441 | $487,579 | $225,454 and $534,024, respectively |
| Operating loss | $249,441 | $487,579 | $225,454 and $534,024, respectively |
| Net income (loss) | $(345,479) | $(1,128,779) | $26,399 income and $(545,112) loss, respectively |
| Operating cash flow | Not separately presented | $(271,996) | $(101,820) for six months |
There were no sales, so gross margin and operating margin are not meaningful. Six-month R&D expense was $6,322, compared with none in 2013. The six-month net loss included $648,655 of interest expense, $182,612 of foreign-currency transaction losses, and an $82,440 income-tax benefit from Australian R&D credits. Net loss per share was $(0.01) for both six-month periods.
At December 31, cash was $14,588, current assets were $52,940, and current liabilities were $1,930,189, resulting in a working-capital deficit of approximately $1.88 million. Total assets were $52,940 and stockholders’ deficit was $1,877,249. Cash declined from $87,799 at June 30. The filing states the company did not have enough available cash to meet obligations over the next 12 months.
Financing activities provided $99,000 for the six months, including $90,000 from convertible notes and $29,000 from common-stock sales, offset by $20,000 of loan repayments. Investing cash flow was zero. Current liabilities included $951,422 of debt settlement payable in stock, net of premium; $453,480 of convertible notes, net; and $50,000 of notes payable. The filing also reports $53,979 of derivative liabilities.
Material changes versus comparable periods
- Quarterly results moved from $26,399 of net income in 2013 to a $345,479 net loss in 2014. Management attributed the deterioration principally to higher interest expense and foreign-currency losses, a smaller favorable derivative revaluation, and higher operating expenses, partly offset by debt-settlement gains and a larger tax benefit.
- Six-month net loss more than doubled to $1,128,779 from $545,112. Interest expense increased to $648,655 from $22,390, largely reflecting debt and settlement premiums, while operating expenses decreased to $487,579 from $534,024.
- Cash used in operations increased to $271,996 from $101,820 for the six-month comparison. Common shares outstanding rose to 130,774,585 at December 31 from 72,684,767 at June 30; 191,688,405 shares were outstanding as of February 16, 2015.
Outlook, risks, contingencies and unusual items
- Going concern: The company reported substantial doubt about its ability to continue as a going concern, citing no revenue, continuing losses and cash use, negative working capital, a stockholders’ deficit and an accumulated deficit of $18,681,696. Management planned to seek additional capital or debt financing, with no assurance it would be available on acceptable terms.
- Debt and dilution: Certain notes have conversion prices tied to a substantial discount to recent trading prices, and some debt was in default. Six convertible notes were convertible into a stated 432,163,062 shares; those shares, and 3 million warrants, were excluded from diluted EPS as anti-dilutive. A July 2014 equity purchase agreement allowed up to $5 million of stock sales at a discount to market, subject to contractual restrictions.
- Settlement obligations: A court-approved creditor settlement created a stock-settled liability of approximately $1.03 million. The company issued 15,587,000 shares in settlement tranches during the six months. In subsequent events, it agreed to issue 10 million shares to settle two notes and 33,259,350 and 17,654,470 shares to settle director balances.
- Development and patents: Management said R&D spending had remained minimal while it sought funding. Patents had been granted in South Africa and New Zealand; the U.S. and European patent offices had made preliminary indications that key features might be patentable. Commercialization depends on further development, financing, patent outcomes and eventual sales.
- Other matters: Foreign-currency transaction losses were significant; the company’s functional currency is the Australian dollar. Derivative liabilities were valued using Level 3 inputs and an option-pricing model. No material pending or threatened litigation was reported. Disclosure controls were deemed ineffective due to a material weakness in segregation of duties; management said it planned to hire accounting personnel when resources permit.
The filing provides no specific revenue, earnings or cash-flow guidance.
Key facts for investors to verify
- Whether the company obtained adequate financing after the filing and can meet near-term obligations.
- Current debt balances, defaults, settlement status, and the potential share impact of discounted-price conversion terms and equity-sale arrangements.
- Post-period share issuance and the resulting fully diluted share count.
- Progress and funding requirements for preclinical work, clinical development and patent protection; the filing does not provide a clear timetable for these milestones.
- Whether the material weakness in disclosure controls was remediated and whether subsequent filings continue to identify going-concern uncertainty.